The trial is taking place at:
P

Palmetto Clinical Research | Summerville, SC

Veeva-enabled site

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Lilly logo

Lilly

Status and phase

Enrolling
Phase 2

Conditions

Diabetic Peripheral Neuropathy

Treatments

Drug: Placebo
Drug: LY3556050

Study type

Interventional

Funder types

Industry

Identifiers

NCT06074562
2023-506127-29-00 (Other Identifier)
J2P-MC-LXBD (Other Identifier)
18509

Details and patient eligibility

About

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.

Enrollment

410 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening.
  • Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) ≤10 at time of screening.
  • Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history.
  • Have a visual analog scale (VAS) pain value ≥40 and <95 during screening.
  • Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for ≥6 months and diagnosed by a score of Part B ≥3 on Michigan Neuropathy Screening Instrument
  • Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.

Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study

  • Have a body mass index ≤45 kilogram/square meter (kg/m²) (inclusive).
  • Are men, or women able to abide by reproductive and contraceptive requirements.

Exclusion criteria

  • History of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP.
  • Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques.
  • Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
  • Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
  • Have in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
  • Have a positive HIV test result at screening.
  • Have a surgery planned during the study for any reason.
  • Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

410 participants in 4 patient groups, including a placebo group

LY3556050 Dose 1
Experimental group
Description:
Participants will receive LY3556050 orally.
Treatment:
Drug: LY3556050
LY3556050 Dose 2
Experimental group
Description:
Participants will receive LY3556050 orally.
Treatment:
Drug: LY3556050
LY3556050 Dose 3
Experimental group
Description:
Participants will receive LY3556050 orally.
Treatment:
Drug: LY3556050
Placebo
Placebo Comparator group
Description:
Participants will receive placebo orally.
Treatment:
Drug: Placebo

Trial contacts and locations

72

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems